MARKET

AXSM

AXSM

Axsome
NASDAQ

Real-time Quotes | Nasdaq Last Sale

77.02
+1.09
+1.44%
Closed 16:00 09/25 EDT
OPEN
76.19
PREV CLOSE
75.93
HIGH
79.93
LOW
76.01
VOLUME
299.99K
TURNOVER
--
52 WEEK HIGH
109.94
52 WEEK LOW
13.64
MARKET CAP
2.87B
P/E (TTM)
-29.1787
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Gilead's $7.25B Debt Offering, Lexicon Deleverages, Taysha Gene Therapies Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 23)
Benzinga · 3d ago
Axsome Therapeutics Presents New Data from MOMENTUM Phase 3 Trial with AXS-07 Demonstrating Rapid Onset of Action and Reduced Symptom Recurrence in the Acute Treatment of Migraine
Significantly faster time to pain relief as compared to rizatriptan (p<0.001)Significantly less relapse of migraine pain as compared to rizatriptan (p=0.001)Benefits demonstrated in patients with a history of inadequate response to prior acute treatmentsNEW YORK, Sept. 24, 2020 (GLOBE NEWSWIRE) --
GlobeNewswire · 3d ago
Axsome' AXS-07 shows faster and durable migraine pain relief as compared to rizatriptan
Axsome Therapeutics (AXSM) says that AXS-07 rapidly relieved and substantially reduced relapse of migraine pain, as compared to active comparator rizatriptan, in Phase 3 (MOMENTUM) trial. Data were presented at the
Seekingalpha · 3d ago
Axsome's AXS-07 tops rizatriptan in migraine study
Axsome Therapeutics (AXSM) says that AXS-07 rapidly relieved and substantially reduced relapse of migraine pain, as compared to active comparator rizatriptan, in Phase 3 (MOMENTUM) trial. Data were presented at the
Seekingalpha · 3d ago
Fintech Focus For September 24, 2020
Benzinga · 4d ago
The Daily Biotech Pulse: Coronavirus Vaccine Updates From J&J & MediciNova, Australian Regulatory Nod For GW Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22)
Benzinga · 4d ago
Axsome Expedites Development Plan for Narcolepsy Candidate
Axsome (AXSM) accelerates the development plan for AXS-12 to treat narcolepsy after a Breakthrough Therapy meeting with the FDA authorities. Stock dips.
Zacks · 5d ago
Axsome Therapeutics (AXSM) Investor Presentation - Slideshow
The following slide deck was published by Axsome Therapeutics, Inc. in conjunction with this event.
Seekingalpha · 6d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AXSM. Analyze the recent business situations of Axsome through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AXSM stock price target is 155.78 with a high estimate of 210.00 and a low estimate of 102.00.
EPS
Institutional Holdings
Institutions: 238
Institutional Holdings: 27.85M
% Owned: 74.70%
Shares Outstanding: 37.28M
TypeInstitutionsShares
Increased
66
3.75M
New
83
-47.78K
Decreased
48
2.36M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/President/Chief Executive Officer/Founder/Director
Herriot Tabuteau
Chief Financial Officer
Nick Pizzie
Chief Operating Officer
Mark Jacobson
Finance Director/Chief Accounting Officer
Joseph Debrah-Affu
Senior Vice President
Amanda Jones
Senior Vice President
Cedric O'Gorman
Other
David Marek
Lead Director/Independent Director
Roger Jeffs
Independent Director
Mark Coleman
Independent Director
Mark Saad
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AXSM
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Axsome Therapeutics Inc stock information, including NASDAQ:AXSM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXSM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AXSM stock methods without spending real money on the virtual paper trading platform.